Potential
Our Team aims to establish personalized treatments to help patients with Stress Urinary Incontinence (SUI) regain control of their lives by offering them minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue.
News
Key Figures
2021
Wyss Zurich admission
20-50
Team size
Wyss Zurich admission
Team size
Project Description
Stress urinary incontinence (SUI) is a highly prevalent and underdiagnosed disorder that affects over 200 million people worldwide. It has a severe impact on physical and psychological health and imposes a high financial burden on affected individuals, healthcare systems, and society.
Women are affected twice as often as men, with an estimated 40% of women above the age of 40 suffering from SUI. Existing treatment options have drawbacks that range from low and short-term efficacy to potentially serious adverse events associated either with invasiveness or the introduction of foreign material, in the case of more potent surgical approaches.
MUVON Therapeutics AG is developing a low-risk, minimally invasive treatment that uses the patient’s own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle, thus potentially providing a cure for SUI.
Contact
Deana Mohr
Project Leader
deana.mohr@wysszurich.ch
Faculty Mentor
Daniel Eberli
Partners and Funding
Project Partners
- University Hospital Zurich
- University of Zurich, BioEntrpreneurship & Innovation (BEI) Program
- University of Zurich, Translational Medicine Accelerator
Funding Partners
- UZH Entrepreneur Fellowship
- EU Horizon 2020
- Innosuisse
- Lichtsteiner Foundation
- Venturelab
- Werner Siemens Foundation
Project Partners
- University Hospital Zurich
- University of Zurich, BioEntrpreneurship & Innovation (BEI) Program
- University of Zurich, Translational Medicine Accelerator
Funding Partners
- UZH Entrepreneur Fellowship
- EU Horizon 2020
- Innosuisse
- Lichtsteiner Foundation
- Venturelab
- Werner Siemens Foundation
